- Home
- LULU vs BBIO Comparison
LULU vs BBIO Comparison
Compare LULU & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LULU | BBIO |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 15.3B |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LULU | BBIO |
|---|---|---|
| Price | $162.46 | $74.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 25 | 25 |
| Target Price | ★ $190.26 | $86.04 |
| AVG Volume (30 Days) | ★ 2.0M | 1.5M |
| Earning Date | 06-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 13.26 | N/A |
| Revenue | ★ $11,102,600,000.00 | $502,076,000.00 |
| Revenue This Year | $5.52 | $89.45 |
| Revenue Next Year | $4.68 | $73.78 |
| P/E Ratio | $12.55 | ★ N/A |
| Revenue Growth | 4.86 | ★ 126.26 |
| 52 Week Low | $143.96 | $31.77 |
| 52 Week High | $340.25 | $84.94 |
Technical Indicators
Market Signals| Indicator | LULU | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 50.63 |
| Support Level | $159.83 | $70.65 |
| Resistance Level | $171.31 | $78.20 |
| Average True Range (ATR) | 5.28 | 2.56 |
| MACD | 1.37 | -0.05 |
| Stochastic Oscillator | 59.22 | 39.89 |
Price Performance
Historical ComparisonAbout LULU lululemon athletica inc.
Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 800 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 45 franchised locations in the Middle East and Europe. The company was founded in 1998 and is based in Vancouver, Canada.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.